Literature DB >> 5417842

Bretylium tosylate in treatment of refractory ventricular arrhythmias complicating myocardial infarction.

G Terry, C W Vellani, M R Higgins, A Doig.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5417842      PMCID: PMC487268          DOI: 10.1136/hrt.32.1.21

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


× No keyword cloud information.
  3 in total

1.  Anti-arrhythmic action of bretylium.

Authors:  P E Leveque
Journal:  Nature       Date:  1965-07-10       Impact factor: 49.962

2.  Bretylium tosylate for suppression of induced ventricular fibrillation.

Authors:  M Bacaner
Journal:  Am J Cardiol       Date:  1966-04       Impact factor: 2.778

3.  Late ventricular dysrhythmias after myocardial infarction.

Authors:  F H Spracklen; E M Besterman; M S Everest; J W Litchfield; M Petrie
Journal:  Br Med J       Date:  1968-11-09
  3 in total
  5 in total

1.  Potassium channel blockade: A mechanism for suppressing ventricular fibrillation.

Authors:  M B Bacaner; J R Clay; A Shrier; R M Brochu
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

2.  Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

Authors:  J L Anderson; D C Harrison; P J Meffin; R A Winkle
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

Review 3.  Beta-adrenergic receptor blocking drugs in cardiac arrhythmias.

Authors:  B N Singh; D E Jewitt
Journal:  Drugs       Date:  1974       Impact factor: 9.546

Review 4.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 5.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.